424 related articles for article (PubMed ID: 21397858)
1. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.
Sawey ET; Chanrion M; Cai C; Wu G; Zhang J; Zender L; Zhao A; Busuttil RW; Yee H; Stein L; French DM; Finn RS; Lowe SW; Powers S
Cancer Cell; 2011 Mar; 19(3):347-58. PubMed ID: 21397858
[TBL] [Abstract][Full Text] [Related]
2. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
Huynh H; Prawira A; Le TBU; Vu TC; Hao HX; Huang A; Wang Y; Porta DG
Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319
[TBL] [Abstract][Full Text] [Related]
3. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
4. Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system.
Latasa MU; Salis F; Urtasun R; Garcia-Irigoyen O; Elizalde M; Uriarte I; Santamaria M; Feo F; Pascale RM; Prieto J; Berasain C; Avila MA
PLoS One; 2012; 7(12):e52711. PubMed ID: 23285165
[TBL] [Abstract][Full Text] [Related]
5. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.
Joshi JJ; Coffey H; Corcoran E; Tsai J; Huang CL; Ichikawa K; Prajapati S; Hao MH; Bailey S; Wu J; Rimkunas V; Karr C; Subramanian V; Kumar P; MacKenzie C; Hurley R; Satoh T; Yu K; Park E; Rioux N; Kim A; Lai WG; Yu L; Zhu P; Buonamici S; Larsen N; Fekkes P; Wang J; Warmuth M; Reynolds DJ; Smith PG; Selvaraj A
Cancer Res; 2017 Dec; 77(24):6999-7013. PubMed ID: 29247039
[TBL] [Abstract][Full Text] [Related]
6. Novel Abs targeting the N-terminus of fibroblast growth factor 19 inhibit hepatocellular carcinoma growth without bile-acid-related side-effects.
Liu H; Zheng S; Hou X; Liu X; Du K; Lv X; Li Y; Yang F; Li W; Sui J
Cancer Sci; 2020 May; 111(5):1750-1760. PubMed ID: 32061104
[TBL] [Abstract][Full Text] [Related]
7. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling.
Teng Y; Zhao H; Gao L; Zhang W; Shull AY; Shay C
Cancer Res; 2017 Nov; 77(22):6215-6225. PubMed ID: 28951455
[TBL] [Abstract][Full Text] [Related]
8. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
Desnoyers LR; Pai R; Ferrando RE; Hötzel K; Le T; Ross J; Carano R; D'Souza A; Qing J; Mohtashemi I; Ashkenazi A; French DM
Oncogene; 2008 Jan; 27(1):85-97. PubMed ID: 17599042
[TBL] [Abstract][Full Text] [Related]
9. Targeting ODC1 inhibits tumor growth through reduction of lipid metabolism in human hepatocellular carcinoma.
Choi Y; Oh ST; Won MA; Choi KM; Ko MJ; Seo D; Jeon TW; Baik IH; Ye SK; Park KU; Park IC; Jang BC; Seo JY; Lee YH
Biochem Biophys Res Commun; 2016 Sep; 478(4):1674-81. PubMed ID: 27592554
[TBL] [Abstract][Full Text] [Related]
10. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
11. Silencing
Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
[TBL] [Abstract][Full Text] [Related]
12. ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma.
Futami T; Okada H; Kihara R; Kawase T; Nakayama A; Suzuki T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
Mol Cancer Ther; 2017 Jan; 16(1):68-75. PubMed ID: 27837028
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M
BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595
[TBL] [Abstract][Full Text] [Related]
14. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
[TBL] [Abstract][Full Text] [Related]
15. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma.
Nishida N; Fukuda Y; Komeda T; Kita R; Sando T; Furukawa M; Amenomori M; Shibagaki I; Nakao K; Ikenaga M
Cancer Res; 1994 Jun; 54(12):3107-10. PubMed ID: 8205525
[TBL] [Abstract][Full Text] [Related]
16. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma.
Ma NF; Hu L; Fung JM; Xie D; Zheng BJ; Chen L; Tang DJ; Fu L; Wu Z; Chen M; Fang Y; Guan XY
Hepatology; 2008 Feb; 47(2):503-10. PubMed ID: 18023026
[TBL] [Abstract][Full Text] [Related]
17. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma.
Zhang YJ; Jiang W; Chen CJ; Lee CS; Kahn SM; Santella RM; Weinstein IB
Biochem Biophys Res Commun; 1993 Oct; 196(2):1010-6. PubMed ID: 8240318
[TBL] [Abstract][Full Text] [Related]
18. [Establishment and cytogenetic characterization of a human hepatocellular carcinoma cell strain from the embolus in portal vein].
Zhang M; Wen JM; Xu JM; Wang WS; Hu L; Xie D; Guan XY
Ai Zheng; 2002 Nov; 21(11):1203-7. PubMed ID: 12526216
[TBL] [Abstract][Full Text] [Related]
19. NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
Lu WJ; Chua MS; Wei W; So SK
Oncotarget; 2015 Oct; 6(30):29847-59. PubMed ID: 26359353
[TBL] [Abstract][Full Text] [Related]
20. Validation of ORAOV1 as a new treatment target in hepatocellular carcinoma.
Ha SY; Yeo SY; Lee KW; Kim SH
J Cancer Res Clin Oncol; 2021 Feb; 147(2):423-433. PubMed ID: 33161447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
